222 related articles for article (PubMed ID: 11751385)
1. LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model.
Cohen LA; Pittman B; Wang CX; Aliaga C; Yu L; Moyer JD
Cancer Res; 2001 Dec; 61(24):8683-8. PubMed ID: 11751385
[TBL] [Abstract][Full Text] [Related]
2. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.
Cohen LA; Marks PA; Rifkind RA; Amin S; Desai D; Pittman B; Richon VM
Anticancer Res; 2002; 22(3):1497-504. PubMed ID: 12168829
[TBL] [Abstract][Full Text] [Related]
3. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.
Bischoff ED; Gottardis MM; Moon TE; Heyman RA; Lamph WW
Cancer Res; 1998 Feb; 58(3):479-84. PubMed ID: 9458093
[TBL] [Abstract][Full Text] [Related]
4. Effects of tamoxifen and melatonin on mammary gland cancer induced by N-methyl-N-nitrosourea and by 7,12-dimethylbenz(a)anthracene, respectively, in female Sprague-Dawley rats.
Kubatka P; Bojková B; M ciková-Kalická K; Mníchová-Chamilová M; Adámeková E; Ahlers I; Ahlersová E; Cermáková M
Folia Biol (Praha); 2001; 47(1):5-10. PubMed ID: 11232869
[TBL] [Abstract][Full Text] [Related]
5. Induction of adipocyte-specific gene expression is correlated with mammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin).
Agarwal VR; Bischoff ED; Hermann T; Lamph WW
Cancer Res; 2000 Nov; 60(21):6033-8. PubMed ID: 11085524
[TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.
Gottardis MM; Bischoff ED; Shirley MA; Wagoner MA; Lamph WW; Heyman RA
Cancer Res; 1996 Dec; 56(24):5566-70. PubMed ID: 8971154
[TBL] [Abstract][Full Text] [Related]
7. Effect of tamoxifen on preneoplastic cell proliferation in N-nitroso-N-methylurea-induced mammary carcinogenesis.
Osborne MP; Ruperto JF; Crowe JP; Rosen PP; Telang NT
Cancer Res; 1992 Mar; 52(6):1477-80. PubMed ID: 1540955
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor profiles: changes in mouse and rat mammary tumors by treatment with selective estrogen receptor modifiers.
Actis AM; Cocca CM; Gutierrez A; Croci M; Rivera ES; Bergoc RM
Med Princ Pract; 2004; 13(4):220-6. PubMed ID: 15181328
[TBL] [Abstract][Full Text] [Related]
9. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid.
Udeani GO; Gerhauser C; Thomas CF; Moon RC; Kosmeder JW; Kinghorn AD; Moriarty RM; Pezzuto JM
Cancer Res; 1997 Aug; 57(16):3424-8. PubMed ID: 9270008
[TBL] [Abstract][Full Text] [Related]
10. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.
Gottardis MM; Jordan VC
Cancer Res; 1987 Aug; 47(15):4020-4. PubMed ID: 3607747
[TBL] [Abstract][Full Text] [Related]
11. Effect of rosiglitazone on N-nitroso-N-methylurea-induced mammary tumors in rat.
Núñez M; Martín G; Cocca C; Mohamad N; Gutiérrez A; Cricco G; Medina V; Rivera E; Croci M; Crescenti E; Bergoc R
Anticancer Res; 2006; 26(3A):2113-22. PubMed ID: 16827153
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA).
Cohen LA; Amin S; Marks PA; Rifkind RA; Desai D; Richon VM
Anticancer Res; 1999; 19(6B):4999-5005. PubMed ID: 10697502
[TBL] [Abstract][Full Text] [Related]
13. Preventive effects of raloxifene and melatonin in N-methyl-N-nitrosourea-induced mammary carcinogenesis in female rats.
Kubatka P; Bojková B; Kalická K; Chamilová M; Adámeková E; Ahlers I; Ahlersová E; Cermáková M
Neoplasma; 2001; 48(4):313-9. PubMed ID: 11712685
[TBL] [Abstract][Full Text] [Related]
14. Effect of tamoxifen on intraperitoneal N-nitroso-N-methylurea induced tumors.
Martin G; Melito G; Rivera E; Levin E; Davio C; Cricco G; Andrade N; Caro R; Bergoc R
Cancer Lett; 1996 Feb; 100(1-2):227-34. PubMed ID: 8620446
[TBL] [Abstract][Full Text] [Related]
15. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
Wu K; Kim HT; Rodriquez JL; Hilsenbeck SG; Mohsin SK; Xu XC; Lamph WW; Kuhn JG; Green JE; Brown PH
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):467-74. PubMed ID: 12010861
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator.
McDougal A; Wormke M; Calvin J; Safe S
Cancer Res; 2001 May; 61(10):3902-7. PubMed ID: 11358803
[TBL] [Abstract][Full Text] [Related]
17. Estradiol and progesterone can prevent rat mammary cancer when administered concomitantly with carcinogen but do not modify surviving tumor histology, estrogen receptor alpha status or Ha-ras mutation frequency.
Swanson SM; Christov K
Anticancer Res; 2003; 23(4):3207-13. PubMed ID: 12931682
[TBL] [Abstract][Full Text] [Related]
18. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
Lubet RA; Boring D; Steele VE; Ruppert JM; Juliana MM; Grubbs CJ
Cancer Prev Res (Phila); 2009 Feb; 2(2):161-7. PubMed ID: 19196723
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma.
Yen WC; Prudente RY; Lamph WW
Breast Cancer Res Treat; 2004 Nov; 88(2):141-8. PubMed ID: 15564797
[TBL] [Abstract][Full Text] [Related]
20. Exceptional chemopreventive activity of low-dose dehydroepiandrosterone in the rat mammary gland.
McCormick DL; Rao KV; Johnson WD; Bowman-Gram TA; Steele VE; Lubet RA; Kellof GJ
Cancer Res; 1996 Apr; 56(8):1724-6. PubMed ID: 8620482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
